Altimmune Inc.
Organization details
- Legal name
- Altimmune Inc.
- Former names
- Pharmathene, Inc Healthcare Acquisition Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Gaithersburg
- Headquarters state / province
- Maryland
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001326190
- EIN
- 20-2726770
Board of directors
-
Alex G. Howarth · DirectorSince 2026
-
Catherine A. Sohn · DirectorSince 2023
-
David Drutz · DirectorSince 2023
-
Diane Jorkasky · DirectorSince 2023
-
Jerome Benedict Durso · Director · President and CEOSince 2025
-
John Gill · DirectorSince 2023
-
Klaus Schafer · DirectorSince 2023
-
Mitchel Sayare · DirectorSince 2023
-
Peter Greenleaf · DirectorSince 2026
-
Philip Hodges · DirectorSince 2023
-
Teri L. Lawver · DirectorSince 2025
-
Vipin K. Garg · Director · President and CEOSince 2023
-
Wayne Pisano · DirectorSince 2023
Chief executives
Board connections
3 of this board's directors also sit on 5 other boards. 5 are in the same sector.
-
Aurinia Pharmaceuticals Inc Same sectorvia Peter Greenleaf
-
Jazz Pharmaceuticals plc Same sectorvia Catherine A. Sohn
-
Maze Therapeutics Inc. Same sectorvia Catherine A. Sohn
-
Oncolytics Biotech Inc. Same sectorvia Wayne Pisano
-
Pelthos Therapeutics Inc. Same sectorvia Peter Greenleaf
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $370,120
- 11 purchases by 6 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | Gregory L. Weaver Officer (Chief Financial Officer) | Option exercise | +14,475 | — | — |
| Oct 1, 2026 | Arbet-Engels Christophe Officer (Chief Medical Officer) | Option exercise | +37,500 | — | — |
| Oct 1, 2026 | Gregory L. Weaver Officer (Chief Financial Officer) | Shares withheld for tax | −4,379 | $2.76 | $12,086 |
| Oct 1, 2026 | Arbet-Engels Christophe Officer (Chief Medical Officer) | Shares withheld for tax | −12,679 | $2.76 | $34,994 |
| Sep 16, 2026 | Richardson Linda M Officer (Chief Commercial Officer) | Option exercise | +24,000 | — | — |
| Sep 16, 2026 | Richardson Linda M Officer (Chief Commercial Officer) | Shares withheld for tax | −6,826 | $3.24 | $22,116 |
| Aug 13, 2026 | Jerome Benedict Durso Director, Officer (President and CEO) | Open-market purchase | +15,000 | $2.95 | $44,250 |
| Jul 31, 2026 | Gregory L. Weaver Officer (Chief Financial Officer) | Grant or award | +1,753 | $2.41 | $4,225 |
| Jul 31, 2026 | Roberts M Scot Officer (Chief Scientific Officer) | Grant or award | +875 | $2.41 | $2,109 |
| Apr 6, 2026 | John Gill Director | Open-market purchase | +9,200 | $3.41 | $31,372 |
| Apr 1, 2026 | Gregory L. Weaver Officer (Chief Financial Officer) | Open-market purchase | +10,000 | $3.15 | $31,500 |
| Apr 1, 2026 | Jerome Benedict Durso Director, Officer (President and CEO) | Open-market purchase | +15,000 | $3.14 | $47,100 |
| Mar 6, 2026 | Gregory L. Weaver Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $3.54 | $17,700 |
| Mar 6, 2026 | Jerome Benedict Durso Director, Officer (President and CEO) | Open-market purchase | +20,000 | $3.54 | $70,800 |
| Feb 2, 2026 | Roberts M Scot Officer (Chief Scientific Officer) | Option exercise | +7,775 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Altimmune Inc.
Who is the CEO of Altimmune Inc.?
Vipin K. Garg is Altimmune Inc.'s President and CEO.
How many directors are on Altimmune Inc.'s board?
Altimmune Inc.'s board has 13 directors: Alex G. Howarth, Catherine A. Sohn, David Drutz, Diane Jorkasky, Jerome Benedict Durso, John Gill, Klaus Schafer, Mitchel Sayare, Peter Greenleaf, Philip Hodges and 3 others.
Are Altimmune Inc. insiders buying or selling shares?
Over the last 12 months, Altimmune Inc. insiders bought $370,120 of shares in 11 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="altimmune-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.